Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

BioSenic provides Financial Update and Financial Calendar 2023

  • Read more about BioSenic provides Financial Update and Financial Calendar 2023

BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)

  • Read more about BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)

BioSenic publie de nouvelles données sur le mécanisme d'action du trioxyde d'arsenic (ATO)

  • Read more about BioSenic publie de nouvelles données sur le mécanisme d'action du trioxyde d'arsenic (ATO)

JTA nouvelle analyse post-hoc de son essai phase III

  • Read more about JTA nouvelle analyse post-hoc de son essai phase III

JTA new post-hoc analysis of its phase III trial

  • Read more about JTA new post-hoc analysis of its phase III trial

ALLOB optimization statistical analysis and complete patient recruitment

  • Read more about ALLOB optimization statistical analysis and complete patient recruitment

ALLOB optimisation de l'analyse statistique et clôture du recrutement des patients

  • Read more about ALLOB optimisation de l'analyse statistique et clôture du recrutement des patients

Accord Pregene

  • Read more about Accord Pregene

Settlement Agreement Pregene

  • Read more about Settlement Agreement Pregene

Couverture Analystes

  • Read more about Couverture Analystes

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions